These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 398013)

  • 1. [(Management of acute toxicity after high dose methotrexate therapy)].
    Urban C; Mutz I; Kotz R; Krisch K
    Onkologie; 1979 Dec; 2(6):238-42. PubMed ID: 398013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vincristine in the etiology of toxicity of high-dose methotrexate therapy.
    Ridgway D; Renholds DC; Neerhout RC; Wolff LJ
    Cancer; 1980 Dec; 46(12):2571-2. PubMed ID: 6969624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
    Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Cohen IJ
    Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
    Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
    Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.
    Grimes DJ; Bowles MR; Buttsworth JA; Thomson DB; Ravenscroft PJ; Nixon PF; Whiting RF; Pond SM
    Drug Saf; 1990; 5(6):447-54. PubMed ID: 2285498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches to cancer chemotherapy with methotrexate.
    Frei E; Jaffe N; Tattersall MH; Pitman S; Parker L
    N Engl J Med; 1975 Apr; 292(16):846-51. PubMed ID: 1078714
    [No Abstract]   [Full Text] [Related]  

  • 9. Normal computed tomograms of the brain in osteosarcoma patients treated with high-dose methotrexate.
    Bowles D; Pratt C; Evans W; Price RA; Coburn T
    Cancer; 1981 Apr; 47(7):1762-5. PubMed ID: 6971702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
    Robert G; Chappé C; Taque S; Bruneau B; Gandemer V
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e100-2. PubMed ID: 24309600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient encephalopathy during the late course of treatment with high-dose methotrexate.
    Fritsch G; Urban C
    Cancer; 1984 May; 53(9):1849-51. PubMed ID: 6584197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
    Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
    Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experiences with high dose methotrexate treatments within the framework of polychemotherapy in osteosarcoma (proceedings)].
    Kotz R
    Z Orthop Ihre Grenzgeb; 1978 Aug; 116(4):539. PubMed ID: 309224
    [No Abstract]   [Full Text] [Related]  

  • 16. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
    Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
    Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
    Kickinger W; Ritschl P; Kotz R
    Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
    Breithaupt H; Küenzlen E
    Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.